SPRINT-MS is a large-scale longitudinal phase II trial including 27 3T MRI scanners to evaluate the treatment of progressive multiple sclerosis with Ibudilast. DTI measures showed high reproducibility in a longitudinal multicenter study, making it appropriate for use as a biomarker. The longitudinal design of the SPRINT-MS trial is expected to mitigate the systematic influence of SNR on DTI, but the observed trend may be useful as a correction factor in cross-sectional studies.
This abstract and the presentation materials are available to members only; a login is required.